Real-World Comparison of Nivolumab/Relatlimab and Nivolumab/Ipilimumab

In this discussion, experts review findings from a large real-world dataset comparing clinical outcomes of 2 frontline combination regimens. They highlight that while clinical trials offer controlled insights, real-world analyses provide complementary perspectives on how therapies perform across diverse patient populations and practice settings.

The panel notes that both regimens demonstrate meaningful survival outcomes, though nuances in toxicity and treatment discontinuation patterns emerge. Factors such as baseline performance status, comorbidities, and treatment sequencing influence outcomes and must be accounted for when interpreting real-world results.

Overall, panelists emphasize the importance of contextualizing real-world evidence alongside clinical trial data. The insights gained from routine practice can help refine treatment selection, improve patient counseling, and align therapeutic expectations with real-world experience.